|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 369.38 USD | +1.07% |
|
+2.69% | -7.23% |
Sales 2024 by Business Segment
Sales 2024 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Biological Products | ||||||||||
Discovery, Development and Commercialization of Rnai Therapeutics | 493M | 844M | 1.04B | 1.83B | 2.25B | |||||
Total Assets | 3.41B | 3.64B | 3.55B | 3.83B | 4.24B | |||||
Interest Expense | -84.5M | -143M | -156M | -121M | -142M | |||||
Income Tax Expense | 2.68M | 680K | 4.16M | 6.72M | -99.22M | |||||
CAPEX | -70.36M | -76.37M | -72.06M | -62.21M | -34.28M | |||||
EBT | -856M | -852M | -1.13B | -434M | -377M | |||||
D&A | 74.44M | 89.69M | 85.55M | 97.03M | 56.67M | |||||
Operating Income | -828M | -709M | -785M | -282M | -177M | |||||
Net Income | -858M | -853M | -1.13B | -440M | -278M |
Geographical Revenue Distribution History
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
United States | 194M | 325M | 473M | 689M | 934M | |||||
Income Tax Expense | - | - | - | - | - | |||||
D&A | - | - | - | - | - | |||||
Total Assets | - | - | - | - | - | |||||
CAPEX | - | - | - | - | - | |||||
Net Income | - | - | - | - | - | |||||
EBT | - | - | - | - | - | |||||
Operating Income | - | - | - | - | - | |||||
Europe | 120M | 260M | 315M | 399M | 516M | |||||
Rest of World | 47.06M | 77.03M | 107M | 153M | 196M |
- Stock Market
- Equities
- ALNY Stock
- Financials Alnylam Pharmaceuticals, Inc.
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition